Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac N.V. (Nasdaq: CVAC) announced the appointment of Myriam Mendila as Chief Development Officer. With over 20 years of experience in global product development, particularly in oncology, Mendila's expertise is expected to strengthen CureVac's mRNA product pipeline. CEO Franz-Werner Haas emphasized her role at this critical juncture for the company, especially following recent positive data updates from COVID-19 and flu programs. Mendila held significant positions at Roche, Genentech, and Novartis, contributing to her strong background in pharmaceutical development. CureVac continues to focus on advancing its clinical pipeline in various therapeutic areas.
CureVac N.V. (Nasdaq:CVAC) announced promising preliminary data from Phase 1 clinical studies focusing on older adults in COVID-19 and seasonal flu programs. In the COVID-19 program, the monovalent mRNA vaccine, CV0501, demonstrated significant neutralizing antibody titers against the BA.1 variant in individuals aged 65 and older. The flu candidate, Flu-SV-mRNA, showed antibody levels approximately 2.3 times higher than those elicited by the licensed vaccine in adults aged 60-80. Both candidates are set for further clinical development stages in collaboration with GSK in 2023.
CureVac N.V. (NASDAQ:CVAC) announced Dr. Franz-Werner Haas will step down as CEO on March 31, 2023, after a decade with the company. Dr. Alexander Zehnder will succeed him from April 1, 2023, bringing extensive experience from roles at Sanofi and Roche. The transition reflects an important phase for CureVac, especially following recent clinical validation of its mRNA technology platform, aiming to establish the company as a commercial player. The leadership change is expected to have significant implications for the company's strategic direction and market positioning.
CureVac (Nasdaq: CVAC) announced positive preliminary data from ongoing Phase 1 studies of its modified mRNA vaccine candidates for COVID-19 and flu. The candidates utilize CureVac's advanced second-generation mRNA backbone which enhances immune responses at lower doses. The COVID-19 monovalent candidate CV0501 showed strong antibody responses against the Omicron variant BA.1, while the flu vaccine candidate Flu-SV-mRNA also demonstrated robust immunogenicity comparable to a licensed vaccine. CureVac plans to advance both candidates to subsequent clinical phases in 2023.
CureVac N.V. (NASDAQ:CVAC) announced the sale of 103,775 common shares by CEO Franz-Werner Haas, CFO Pierre Kemula, and Interim CDO Ulrike Gnad-Vogt. The sales were conducted solely to meet tax and social security liabilities from a legacy Virtual Stock Option Plan. Management clarified that they do not plan any additional share sales in the near future. Established in Tübingen, Germany, CureVac specializes in mRNA technology and has over 20 years of experience in developing therapeutic solutions.
CureVac (Nasdaq: CVAC) reported third-quarter 2022 revenues of €11.2 million, down 62% year-over-year, primarily due to the terminated collaboration with Boehringer Ingelheim. The company continues to progress its second-generation mRNA vaccine candidates in collaboration with GSK, with four Phase 1 trials underway and results expected in Q1 2023. Operating losses decreased to €52.4 million, while cash reserves stood at €540.9 million. CureVac plans to broaden its oncology initiatives with two proof-of-principle studies set to start in 2023, aiming to enhance its mRNA technology applications in cancer treatment.
CureVac N.V. (Nasdaq: CVAC) announced preliminary findings from the Phase 1 expansion study of CV8102, its oncology candidate. The data confirm the treatment's safety and its capability to activate the immune system against tumors. In a cohort of 30 patients treated with CV8102 and anti-PD-1 antibodies, 17% experienced partial responses lasting up to a year. No responses were seen in the single-agent cohort of 10 patients. Final Phase 1 data are expected in H1 2023, which will be published in a peer-reviewed journal.
CureVac N.V. (NASDAQ:CVAC) will report third quarter and first nine months 2022 financial results on November 16, 2022. A conference call will occur at 3 p.m. CET / 9 a.m. ET, allowing investors and stakeholders access to important business updates. CureVac is focused on developing mRNA-based therapies and is engaged in collaborations for vaccines against infectious diseases, including COVID-19. The company's technology aims to instruct the body to produce proteins that combat various diseases. More details are available on their website.
CureVac N.V. (Nasdaq: CVAC) reported its Q2 2022 financial results, revealing revenues of €20.1 million, a 10% decline year-over-year. Cash reserves stood at €573.6 million, down from €811.5 million as of December 2021. The company initiated Phase 1 trials for its modified COVID-19 vaccine candidate CV0501 targeting the Omicron variant and for the modified influenza vaccine FLU SV mRNA, developed in partnership with GSK. Additionally, CureVac acquired Frame Cancer Therapeutics to bolster its oncology strategy.